Cargando…
The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206805/ https://www.ncbi.nlm.nih.gov/pubmed/34149730 http://dx.doi.org/10.3389/fimmu.2021.689132 |
_version_ | 1783708687753281536 |
---|---|
author | Ren, Sijia Xiong, Xinxin You, Hua Shen, Jianfei Zhou, Penghui |
author_facet | Ren, Sijia Xiong, Xinxin You, Hua Shen, Jianfei Zhou, Penghui |
author_sort | Ren, Sijia |
collection | PubMed |
description | Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from the increase in the expression of pro-angiogenic factors, which is involved in the regulation of the function and migration of immune cells. Anti-angiogenic agents can normalize blood vessels, and thus transforming the tumor microenvironment from immunosuppressive to immune-supportive by increasing the infiltration and activation of immune cells. Therefore, the combination of immunotherapy with anti-angiogenesis is a promising strategy for cancer treatment. Here, we outline the current understanding of the mechanisms of vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) signaling in tumor immune escape and progression, and summarize the preclinical studies and current clinical data of the combination of ICB and anti-angiogenic drugs in the treatment of advanced NSCLC. |
format | Online Article Text |
id | pubmed-8206805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82068052021-06-17 The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer Ren, Sijia Xiong, Xinxin You, Hua Shen, Jianfei Zhou, Penghui Front Immunol Immunology Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from the increase in the expression of pro-angiogenic factors, which is involved in the regulation of the function and migration of immune cells. Anti-angiogenic agents can normalize blood vessels, and thus transforming the tumor microenvironment from immunosuppressive to immune-supportive by increasing the infiltration and activation of immune cells. Therefore, the combination of immunotherapy with anti-angiogenesis is a promising strategy for cancer treatment. Here, we outline the current understanding of the mechanisms of vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) signaling in tumor immune escape and progression, and summarize the preclinical studies and current clinical data of the combination of ICB and anti-angiogenic drugs in the treatment of advanced NSCLC. Frontiers Media S.A. 2021-06-02 /pmc/articles/PMC8206805/ /pubmed/34149730 http://dx.doi.org/10.3389/fimmu.2021.689132 Text en Copyright © 2021 Ren, Xiong, You, Shen and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ren, Sijia Xiong, Xinxin You, Hua Shen, Jianfei Zhou, Penghui The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer |
title | The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer |
title_full | The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer |
title_fullStr | The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer |
title_full_unstemmed | The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer |
title_short | The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer |
title_sort | combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206805/ https://www.ncbi.nlm.nih.gov/pubmed/34149730 http://dx.doi.org/10.3389/fimmu.2021.689132 |
work_keys_str_mv | AT rensijia thecombinationofimmunecheckpointblockadeandangiogenesisinhibitorsinthetreatmentofadvancednonsmallcelllungcancer AT xiongxinxin thecombinationofimmunecheckpointblockadeandangiogenesisinhibitorsinthetreatmentofadvancednonsmallcelllungcancer AT youhua thecombinationofimmunecheckpointblockadeandangiogenesisinhibitorsinthetreatmentofadvancednonsmallcelllungcancer AT shenjianfei thecombinationofimmunecheckpointblockadeandangiogenesisinhibitorsinthetreatmentofadvancednonsmallcelllungcancer AT zhoupenghui thecombinationofimmunecheckpointblockadeandangiogenesisinhibitorsinthetreatmentofadvancednonsmallcelllungcancer AT rensijia combinationofimmunecheckpointblockadeandangiogenesisinhibitorsinthetreatmentofadvancednonsmallcelllungcancer AT xiongxinxin combinationofimmunecheckpointblockadeandangiogenesisinhibitorsinthetreatmentofadvancednonsmallcelllungcancer AT youhua combinationofimmunecheckpointblockadeandangiogenesisinhibitorsinthetreatmentofadvancednonsmallcelllungcancer AT shenjianfei combinationofimmunecheckpointblockadeandangiogenesisinhibitorsinthetreatmentofadvancednonsmallcelllungcancer AT zhoupenghui combinationofimmunecheckpointblockadeandangiogenesisinhibitorsinthetreatmentofadvancednonsmallcelllungcancer |